Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
Would you use R2CHOP to treat DLBCL based on the results of the E1412 study?
Related Questions
When would you consider using a BTK inhibitor in the frontline setting for lymphoplasmacytic lymphoma (LPL) or Waldenstrom's Macroglobulinemia?
How would you approach treatment for a R/R mantle cell lymphoma patient with a history of autoimmune hepatitis who has progressed on both a covalent and non-covalent BTKi?
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
What is your standard approach to treatment of plasmablastic lymphoma in HIV negative patients?
When would you consider treating an asymptomatic patient with follicular lymphoma?
How do you choose between axicabtagene ciloleucel and tisagenlecleucel in patients with follicular lymphoma for whom you are recommending CAR T-cell therapy?
Will you recommend pirtobrutinib following a prior covalent BTKi in patients with cardiac comorbidities?
Have you utilized a dose-reduced approach for elderly patients receiving frontline Pola-R-CHP similar to R-miniCHOP?
What is your treatment approach to newly diagnosed primary effusion lymphoma?
What is your preferred second line regimen for follicular lymphoma that has relapsed four years out since receiving BR?
